Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas ... Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.005 | -6.84931506849 | 0.073 | 0.073 | 0.066 | 638713 | 0.07121831 | DE |
| 4 | -0.006 | -8.10810810811 | 0.074 | 0.079 | 0.066 | 815644 | 0.07330983 | DE |
| 12 | -0.008 | -10.5263157895 | 0.076 | 0.093 | 0.065 | 980201 | 0.07576731 | DE |
| 26 | -0.013 | -16.049382716 | 0.081 | 0.1 | 0.065 | 1039231 | 0.08170182 | DE |
| 52 | -0.008 | -10.5263157895 | 0.076 | 0.125 | 0.065 | 1270562 | 0.08787469 | DE |
| 156 | 0.022 | 47.8260869565 | 0.046 | 0.21 | 0.043 | 1753676 | 0.10603047 | DE |
| 260 | 0.019 | 38.7755102041 | 0.049 | 0.21 | 0.02 | 1756640 | 0.0856145 | DE |
georgejjl
5分前
DrHigh
7分前
Lone Clone
7分前
CryptoRain
7分前
Fund_Analyst
7分前
Wallstreeter$$$
8分前
Jack_Bolander
8分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。